Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.
<h4>Objectives</h4>We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL-producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/079d29abbbde4574bbafe24c270f363c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:079d29abbbde4574bbafe24c270f363c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:079d29abbbde4574bbafe24c270f363c2021-12-02T20:06:14ZRelay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study.1932-620310.1371/journal.pone.0257217https://doaj.org/article/079d29abbbde4574bbafe24c270f363c2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257217https://doaj.org/toc/1932-6203<h4>Objectives</h4>We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL-producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used.<h4>Materials and methods</h4>We retrospectively identified children <18 years who were included in a previous prospective observational multicentric study on managing FUTI due to ESBL-E between 2014 and 2017 in France. We collected whether children who received cotrimoxazole, ciprofloxacin or the AC-cefixime combination as the oral relay therapy reported a recurrence within the first month after the end of treatment. Then, we analyzed the susceptibility drug-testing of the strains involved.<h4>Results</h4>We included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination.<h4>Conclusions</h4>The AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin.Gabriel LignieresAndré BirgyCamille JungStéphane BonacorsiCorinne LevyFrançois AngoulvantEmmanuel GrimprelMarie Aliette DommerguesYves GilletIrina CraiuAlexis RybakLoic De PontualFrançois DubosEmmanuel CixousVincent GajdosDidier PinquierIsabelle AndriantahinaValérie Soussan-BaniniEmilie GeorgetElise LaunayOlivier VignaudRobert CohenFouad MadhiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 9, p e0257217 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Gabriel Lignieres André Birgy Camille Jung Stéphane Bonacorsi Corinne Levy François Angoulvant Emmanuel Grimprel Marie Aliette Dommergues Yves Gillet Irina Craiu Alexis Rybak Loic De Pontual François Dubos Emmanuel Cixous Vincent Gajdos Didier Pinquier Isabelle Andriantahina Valérie Soussan-Banini Emilie Georget Elise Launay Olivier Vignaud Robert Cohen Fouad Madhi Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| description |
<h4>Objectives</h4>We need studies assessing therapeutic options for oral relay in febrile urinary tract infection (FUTI) due to ESBL-producing Enterobacteriaceae (ESBL-E) in children. Amoxicillin-clavulanate/cefixime (AC-cefixime) combination seems to be a suitable option. We sought to describe the risk of recurrence at 1 month after the end of treatment for FUTI due to ESBL-E according to the oral relay therapy used.<h4>Materials and methods</h4>We retrospectively identified children <18 years who were included in a previous prospective observational multicentric study on managing FUTI due to ESBL-E between 2014 and 2017 in France. We collected whether children who received cotrimoxazole, ciprofloxacin or the AC-cefixime combination as the oral relay therapy reported a recurrence within the first month after the end of treatment. Then, we analyzed the susceptibility drug-testing of the strains involved.<h4>Results</h4>We included 199 children who received an oral relay therapy with cotrimoxazole (n = 72, 36.2%), ciprofloxacin (n = 38, 19.1%) or the AC-cefixime combination (n = 89, 44.7%). Nine (4.5%) patients had a recurrence within the first month after the end of treatment, with no difference between the 3 groups of oral relay (p = 0.8): 4 (5.6%) cotrimoxazole, 2 (5.3%) ciprofloxacin and 3 (3.4%) AC-cefixime combination. Phenotype characterization of 249 strains responsible for FUTI due to ESBL-E showed that 97.6% were susceptible to the AC-cefixime combination.<h4>Conclusions</h4>The AC-cefixime combination represents an interesting therapeutic option for oral relay treatment of FUTI due to ESBL-E as the recurrence rate at 1 month after the end of treatment was the same when compared to cotrimoxazole and ciprofloxacin. |
| format |
article |
| author |
Gabriel Lignieres André Birgy Camille Jung Stéphane Bonacorsi Corinne Levy François Angoulvant Emmanuel Grimprel Marie Aliette Dommergues Yves Gillet Irina Craiu Alexis Rybak Loic De Pontual François Dubos Emmanuel Cixous Vincent Gajdos Didier Pinquier Isabelle Andriantahina Valérie Soussan-Banini Emilie Georget Elise Launay Olivier Vignaud Robert Cohen Fouad Madhi |
| author_facet |
Gabriel Lignieres André Birgy Camille Jung Stéphane Bonacorsi Corinne Levy François Angoulvant Emmanuel Grimprel Marie Aliette Dommergues Yves Gillet Irina Craiu Alexis Rybak Loic De Pontual François Dubos Emmanuel Cixous Vincent Gajdos Didier Pinquier Isabelle Andriantahina Valérie Soussan-Banini Emilie Georget Elise Launay Olivier Vignaud Robert Cohen Fouad Madhi |
| author_sort |
Gabriel Lignieres |
| title |
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| title_short |
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| title_full |
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| title_fullStr |
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| title_full_unstemmed |
Relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children: A French multicenter study. |
| title_sort |
relay oral therapy in febrile urinary tract infections caused by extended spectrum beta-lactamase-producing enterobacteriaceae in children: a french multicenter study. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/079d29abbbde4574bbafe24c270f363c |
| work_keys_str_mv |
AT gabriellignieres relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT andrebirgy relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT camillejung relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT stephanebonacorsi relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT corinnelevy relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT francoisangoulvant relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT emmanuelgrimprel relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT mariealiettedommergues relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT yvesgillet relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT irinacraiu relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT alexisrybak relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT loicdepontual relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT francoisdubos relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT emmanuelcixous relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT vincentgajdos relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT didierpinquier relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT isabelleandriantahina relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT valeriesoussanbanini relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT emiliegeorget relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT eliselaunay relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT oliviervignaud relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT robertcohen relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy AT fouadmadhi relayoraltherapyinfebrileurinarytractinfectionscausedbyextendedspectrumbetalactamaseproducingenterobacteriaceaeinchildrenafrenchmulticenterstudy |
| _version_ |
1718375403133861888 |